Heart Drug Improved Right Ventricular Function in Study
Aficamten treatment resulted in small but measurable heart pressure changes for patients with obstructive hypertrophic cardiomyopathy.
Updated on Oct. 11, 2026 in Heart Disease
Live Poll
Do you trust that new heart medications provide meaningful, long-term health improvements for patients?
Researchers presented data from the phase 3 SEQUOIA-HCM trial showing that aficamten reduced right ventricular systolic pressure in patients with obstructive hypertrophic cardiomyopathy. This new analysis offers insight into how the medication affects the right side of the heart for those managing this chronic condition.
Why it matters
Understanding how medications impact the right ventricle is crucial for managing obstructive hypertrophic cardiomyopathy, a condition that often affects the entire heart's efficiency. This research addresses a gap in existing evidence regarding the secondary effects of specialized cardiac therapies.
In a phase 3 trial of 282 patients with obstructive hypertrophic cardiomyopathy, researchers used echocardiography to track heart function over 24 weeks. The treatment led to a 1.2 percent reduction in right ventricular free wall longitudinal strain and a 4.3 mmHg drop in systolic pressure.
The players
SEQUOIA-HCM
A phase 3 clinical trial investigating the efficacy and safety of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
HFSA
The Heart Failure Society of America is a professional organization dedicated to the advancement of heart failure research and patient care standards.
The details
The investigators utilized speckle-tracking echocardiography to monitor how the heart muscle deforms during contractions, allowing them to isolate specific functional changes. By applying multivariable linear regression, the team evaluated whether these structural shifts in the right ventricle were linked to broader clinical outcomes. While the drug influenced pressure and wall strain, these measurements did not show a significant association with changes in the patients' New York Heart Association functional class.
Timeline
The HFSA Scientific Meeting in Phoenix commenced on 2026-10-09.
The HFSA Scientific Meeting concluded on 2026-10-12.
Health Landscape
This analysis builds upon the evidence base established by the SEQUOIA-HCM clinical trial regarding specialized therapies for obstructive hypertrophic cardiomyopathy. It represents a shift toward more comprehensive cardiac monitoring, moving beyond simple left-sided heart assessments.
Patients managing hypertrophic cardiomyopathy should discuss how their treatment plan accounts for overall heart health during their next cardiology consultation. It is worth asking your doctor which specific cardiac markers, such as ventricular pressure, are most relevant for monitoring your condition.
The takeaway
While aficamten demonstrated measurable impacts on right ventricular pressure, these findings were not clearly linked to daily functional improvements in the study cohort. Patients should continue to prioritize symptom tracking and regular follow-ups with a cardiologist to monitor heart health.
Further reading
Learn more about advancements in managing Heart Disease.
More information
Review the trial details on the SEQUOIA-HCM clinical trial registry page.
Source note: This article includes information reported by Hcplive.
Live Poll
Do you trust that new heart medications provide meaningful, long-term health improvements for patients?
